Your browser doesn't support javascript.
loading
A new formulation of dezocine, Cyc-dezocine, reduces oxycodone self-administration in female and male rats.
Schmidt, Heath D; Zhang, Yafang; Xi, Jin; Zanni, Giulia; Liu, Renyu; Barr, Gordon A.
Affiliation
  • Schmidt HD; Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Zhang Y; Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Xi J; Department of Anesthesiology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, USA.
  • Zanni G; Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, USA.
  • Liu R; Department of Anesthesiology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, USA.
  • Barr GA; Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, USA; Department of Anesthesiology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, USA; Department of Psychology, University of Pennsylvania, USA. Electronic address: bar
Neurosci Lett ; 815: 137479, 2023 10 15.
Article in En | MEDLINE | ID: mdl-37714288
Dezocine is a partial mu opioid receptor agonist previously used as an analgesic for perioperative acute pain in the US and is now the most used perioperative analgesic in China. In general, dezocine is well-tolerated, with relatively minimal risk of fatal respiratory depression. To our knowledge, there are no reports of dezocine addiction, which suggests that the abuse liability of dezocine is low. The overarching goal of this study was to determine the efficacy of a novel formulation of dezocine (Cyc-dezocine), developed for intraperitoneal or intranasal administration, to reduce voluntary opioid taking in rats. One cohort of male rats self-administered intravenous oxycodone on a fixed-ratio 5 schedule of reinforcement. Once oxycodone taking stabilized, rats were pretreated with systemic injections of vehicle or Cyc-dezocine. Cyc-dezocine dose-dependently reduced intravenous oxycodone self-administration. A second cohort of male and female rats self-administered oral oxycodone from drinking water. Once oxycodone taking stabilized, rats were pretreated with intra-nasal Cyc-dezocine. Consistent with the effects of i.p. Cyc-dezocine in our intravenous oxycodone studies, intra-nasal Cyc-dezocine attenuated oral oxycodone self-administration. Together, these findings support the need for further studies investigating the therapeutic potential of Cyc-dezocine for treating opioid use disorder.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxycodone / Analgesics, Opioid Limits: Animals / Female / Humans / Male Language: En Journal: Neurosci Lett Year: 2023 Document type: Article Affiliation country: United States Country of publication: Ireland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxycodone / Analgesics, Opioid Limits: Animals / Female / Humans / Male Language: En Journal: Neurosci Lett Year: 2023 Document type: Article Affiliation country: United States Country of publication: Ireland